<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856609</url>
  </required_header>
  <id_info>
    <org_study_id>999909095</org_study_id>
    <secondary_id>09-DK-N095</secondary_id>
    <nct_id>NCT00856609</nct_id>
  </id_info>
  <brief_title>The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects</brief_title>
  <official_title>The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes;
      it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic
      islet cells and delaying gastric emptying. This randomized, placebo-controlled study is to
      evaluate whether exenatide over a 5 week period in non-diabetic obese subjects may lead to
      weight loss. To control for variability in individual response to weight loss treatment, this
      study will assess the role of exenatide in changing food intake and energy expenditure as
      possible sources of weight loss. This study will also evaluate the safety profile of
      exenatide in non-diabetic obese people. Additional assessments will evaluate changes in body
      fat and hormones involved in the sensations of hunger and fullness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity can lead to a number of health problems including diabetes, heart disease, stroke,
      low back pain, fatty liver disease, and osteoarthritis. The medical treatments currently
      available for obesity are limited. Exenatide is an injectable medication approved for
      treatment of type 2 diabetes that causes weight loss in some diabetic subjects. The reasons
      exenatide is thought to cause weight loss include decreased food intake, increased feelings
      of fullness and nausea. Because levels of a human gut hormone (glucagon like peptide 1) that
      is similar to exenatide have been shown to be related to resting energy expenditure, it is
      also possible that exenatide may have effects on a person s metabolism, a.k.a. energy
      expenditure, but any effect of exenatide on energy expenditure has yet to be evaluated. Even
      though exenatide is used to treat diabetes, administration of exenatide to non-diabetic lean
      individuals did not cause frankly low blood sugars.

      The primary goal of this study is to investigate the way in which exenatide given twice a day
      to obese (BMI &gt;= 30 kg/m^2) people without diabetes might lead to weight loss. Because
      response to weight loss treatment can be highly variable between individuals, we will look at
      the role of exenatide in changing food intake and energy expenditure as possible explanations
      for weight loss. We will also assess the safety profile of exenatide in non-diabetic obese
      people.

      This study will involve the use of exenatide or placebo, determined randomly, in obese
      individuals without diabetes over a 5 week period. The primary measurements will include
      effects of exenatide on energy expenditure and food intake. We will also look at changes in
      body fat and the levels of hormones involved in the sensations of hunger and fullness. We
      will assess if any exenatide-induced changes can predict which individuals lose weight over
      the 5 weeks. The safety and side effects of exenatide in non-diabetic individuals during this
      time will also be determined. Findings from this study would help to determine how exenatide
      works to cause weight loss in people without diabetes, who might benefit most, and would help
      to improve understanding of why some people respond better to weight loss treatment than
      others.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 3, 2009</start_date>
  <completion_date type="Actual">September 19, 2016</completion_date>
  <primary_completion_date type="Actual">September 19, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Energy Intake</measure>
    <time_frame>Day 6-7-8 (at baseline) and Day 2-13-14 (3 days after starting study intervention)</time_frame>
    <description>Mean of 3-day food intake change between 3 days (Day 6-7-8) at baseline assessment and 3 days (Day 12-13-14) during the intervention period between the exenatide and placebo groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Twenty-four-hour Energy Expenditure</measure>
    <time_frame>Day 5 and Day 11</time_frame>
    <description>Change of twenty-four-hour energy expenditure between at Day 5 at baseline assessment and at Day 11 two days after starting study medication between the exenatide and placebo groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>5 weeks</time_frame>
    <description>Mean decrease between pre- and post-randomization in 5 Weeks between the exenatide and placebo groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Weight Loss</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 micrograms subcutaneously twice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Byetta (exenatide)</intervention_name>
    <description>Exenatide is an injectable medication</description>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight loss</intervention_name>
    <description>Because response to weight loss</description>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metabolic Chamber</intervention_name>
    <description>The subject stays in the small room</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Premenopausal women and men &lt; 55 years of age

          -  BMI &gt;30 kg/m(2)

          -  Expressed desire for weight loss

          -  Stable weight (variation &lt; 2.3 kg within past 6 months)

          -  Ability to provide informed consent

          -  Ability to follow verbal and written instructions

          -  Nonsmoker

          -  Ability to commute to study site on a regular basis for short outpatient visits over 5
             weeks

          -  For females, use of a medically approved form of contraception. For oral
             contraceptives, subjects will need to be on an established dose for at least 3 months
             to ensure stable weight and will be asked not to switch contraceptive methods during
             study participation.

        EXCLUSION CRITERIA:

          -  Age &lt; 18 years

          -  Use of other medications to treat obesity including medications obtained over the
             counter or internet, orlistat (Xenical, Alli), sibutramine (Meridia), topiramate (with
             or without phentermine (Qsymia), phentermine (Adipex P) or lorcaserin (Belviq) within
             the past 6 months

          -  History of an eating disorder including anorexia or bulimia

          -  History of surgery for the treatment of obesity (gastric banding, gastric bypass)

          -  Diagnosis of type 1 or type 2 diabetes mellitus according to American Diabetes
             Association guidelines

          -  Previous exposure to exenatide

          -  Uncontrolled hypertension as defined by a blood pressure of 150/90 on two or more
             occasions or use of antihypertensive medications which may affect energy expenditure
             including alpha blockers, beta blockers, angiotensin receptor blockers or inhibitors
             of angiotensin converting enzyme

          -  Current use of tobacco products, marijuana, amphetamines, cocaine or intravenous drug
             use

          -  Chronic ethanol use (&gt; 3 drinks /day)

          -  Endocrine disorders including hypo or hyperthyroidism (including subclinical disease),
             Cushing s disease, growth hormone deficiency or other pituitary diseases

          -  History of pancreatitis

          -  Personal or family history of multiple endocrine neoplasia (MEN)-2 or medullary
             thyroid cancer

          -  History of unresolved gallstones

          -  Hyperamylasemia

          -  Fasting triglyceride level greater than or equal to 500

          -  Gastroparesis

          -  Inflammatory bowel disease or malabsorption disorders

          -  Malignancy treated with chemotherapy or radiation within the past 5 years

          -  Current clinical depression, diagnosis of psychosis or recent use of psychotropic
             medication

          -  Pregnancy within past 6 months

          -  Breastfeeding

          -  Failure to use medically approved contraceptive methods if subject is female

          -  Liver function abnormalities (transaminases greater than twice normal)

          -  Renal insufficiency (creatinine clearance &lt; 50 ml/min)

          -  History of chronic infection including tuberculosis, coccidiomycoses, lyme disease or
             HIV infection

          -  Pulmonary disorders, including chronic obstructive pulmonary disease, which would
             limit ability to follow the protocol (investigator judgment)

          -  Cardiovascular disease including history of myocardial infarction, unstable angina or
             heart failure

          -  Central nervous system disease, including history of cerebrovascular accidents,
             dementia, and neurodegenerative disorders

          -  Weight &lt;450 pounds (maximum weight of the DXA machine as per manufacturer s manual)

          -  Sensitivity to exenatide or any inert components in its formulation

          -  Sensitivity to acetaminophen

          -  Conditions not specifically mentioned above may serve as criteria for exclusion at the
             discretion of the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Krakoff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIDDK, Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007 Jan;29(1):139-53.</citation>
    <PMID>17379054</PMID>
  </reference>
  <reference>
    <citation>Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 Nov;27(11):2628-35.</citation>
    <PMID>15504997</PMID>
  </reference>
  <reference>
    <citation>Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007 Jul 11;298(2):194-206. Review.</citation>
    <PMID>17622601</PMID>
  </reference>
  <verification_date>September 19, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <results_first_submitted>September 18, 2017</results_first_submitted>
  <results_first_submitted_qc>December 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2018</results_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weight Loss</keyword>
  <keyword>Byetta (Exenatide)</keyword>
  <keyword>Energy Expenditure</keyword>
  <keyword>Food Intake</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of 150 planned total number of enrollment, 145 participants were recruited. Among the 145 participants, 84 participants met inclusion criteria. Only 80 participants out of 84 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide</title>
          <description>10 micrograms subcutaneously twice
Byetta (exenatide): Exenatide is an injectable medication
Weight loss: Because response to weight loss</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Twice daily
Metabolic Chamber: The subject stays in the small room
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exenatide</title>
          <description>10 micrograms subcutaneously twice
Byetta (exenatide): Exenatide is an injectable medication
Weight loss: Because response to weight loss</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Twice daily
Metabolic Chamber: The subject stays in the small room
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="8.4"/>
                    <measurement group_id="B2" value="33.7" spread="9.0"/>
                    <measurement group_id="B3" value="34.4" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105.5" spread="19.2"/>
                    <measurement group_id="B2" value="108.8" spread="20.7"/>
                    <measurement group_id="B3" value="107.1" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="6.6"/>
                    <measurement group_id="B2" value="38.2" spread="6.8"/>
                    <measurement group_id="B3" value="38.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat free mass</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="11.5"/>
                    <measurement group_id="B2" value="37.9" spread="8.7"/>
                    <measurement group_id="B3" value="36.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat mass</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="8.8"/>
                    <measurement group_id="B2" value="30.8" spread="8.7"/>
                    <measurement group_id="B3" value="29.4" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body fat</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" spread="6.9"/>
                    <measurement group_id="B2" value="44.4" spread="8.7"/>
                    <measurement group_id="B3" value="44.2" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.9" spread="8.5"/>
                    <measurement group_id="B2" value="98.8" spread="8.8"/>
                    <measurement group_id="B3" value="97.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Two-hour glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139.4" spread="25.7"/>
                    <measurement group_id="B2" value="135.1" spread="25.6"/>
                    <measurement group_id="B3" value="137.2" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean energy intake</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3495.5" spread="1169.6"/>
                    <measurement group_id="B2" value="3093.5" spread="992.3"/>
                    <measurement group_id="B3" value="3294.5" spread="1096.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of calories needed for weight maintenance participants consumed</title>
          <units>Percentage of Carlories</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119.3" spread="42.1"/>
                    <measurement group_id="B2" value="105.4" spread="29.6"/>
                    <measurement group_id="B3" value="112.3" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carbohydrates intake</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1785.5" spread="595.5"/>
                    <measurement group_id="B2" value="1593.8" spread="476.1"/>
                    <measurement group_id="B3" value="1689.7" spread="544.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat intake</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1305.3" spread="488.4"/>
                    <measurement group_id="B2" value="1130.9" spread="484.6"/>
                    <measurement group_id="B3" value="1218.1" spread="491.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Protein intake</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="434.2" spread="159.5"/>
                    <measurement group_id="B2" value="396.9" spread="139.6"/>
                    <measurement group_id="B3" value="415.6" spread="150.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Soda intake</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206.5" spread="191.3"/>
                    <measurement group_id="B2" value="183.3" spread="169.1"/>
                    <measurement group_id="B3" value="195.0" spread="159.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24 hour energy expenditure</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2319.3" spread="377.0"/>
                    <measurement group_id="B2" value="2333.8" spread="422.0"/>
                    <measurement group_id="B3" value="2325.9" spread="385.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory quotient</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.86" spread="0.03"/>
                    <measurement group_id="B2" value="0.85" spread="0.03"/>
                    <measurement group_id="B3" value="0.86" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carbohydrate oxidation</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1121.1" spread="353.5"/>
                    <measurement group_id="B2" value="1068.4" spread="322.5"/>
                    <measurement group_id="B3" value="1097.0" spread="338.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipid Oxidation</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="781.0" spread="330.2"/>
                    <measurement group_id="B2" value="873.5" spread="377.6"/>
                    <measurement group_id="B3" value="823.3" spread="353.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sleeping metabolic rate</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1818.1" spread="277.5"/>
                    <measurement group_id="B2" value="1800.6" spread="286.5"/>
                    <measurement group_id="B3" value="1810.1" spread="279.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Awake fed thermogenesis</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="629.9" spread="176.3"/>
                    <measurement group_id="B2" value="671.0" spread="232.0"/>
                    <measurement group_id="B3" value="648.7" spread="203.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spontaneous physical activity</title>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.4" spread="47.1"/>
                    <measurement group_id="B2" value="79.4" spread="43.4"/>
                    <measurement group_id="B3" value="80.0" spread="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Energy Intake</title>
        <description>Mean of 3-day food intake change between 3 days (Day 6-7-8) at baseline assessment and 3 days (Day 12-13-14) during the intervention period between the exenatide and placebo groups</description>
        <time_frame>Day 6-7-8 (at baseline) and Day 2-13-14 (3 days after starting study intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>10 micrograms subcutaneously twice
Byetta (exenatide): Exenatide is an injectable medication
Weight loss: Because response to weight loss</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Twice daily
Metabolic Chamber: The subject stays in the small room
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Energy Intake</title>
          <description>Mean of 3-day food intake change between 3 days (Day 6-7-8) at baseline assessment and 3 days (Day 12-13-14) during the intervention period between the exenatide and placebo groups</description>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1016.1" spread="724.5"/>
                    <measurement group_id="O2" value="245.1" spread="710.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANCOVA</method>
            <param_type>Slope</param_type>
            <param_value>-624.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-901.8</ci_lower_limit>
            <ci_upper_limit>-347.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Twenty-four-hour Energy Expenditure</title>
        <description>Change of twenty-four-hour energy expenditure between at Day 5 at baseline assessment and at Day 11 two days after starting study medication between the exenatide and placebo groups</description>
        <time_frame>Day 5 and Day 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>10 micrograms subcutaneously twice
Byetta (exenatide): Exenatide is an injectable medication
Weight loss: Because response to weight loss</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Twice daily
Metabolic Chamber: The subject stays in the small room
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Twenty-four-hour Energy Expenditure</title>
          <description>Change of twenty-four-hour energy expenditure between at Day 5 at baseline assessment and at Day 11 two days after starting study medication between the exenatide and placebo groups</description>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" spread="157.2"/>
                    <measurement group_id="O2" value="28.9" spread="119.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANCOVA</method>
            <param_type>Slope</param_type>
            <param_value>-24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-89.7</ci_lower_limit>
            <ci_upper_limit>41.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight</title>
        <description>Mean decrease between pre- and post-randomization in 5 Weeks between the exenatide and placebo groups.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>10 micrograms subcutaneously twice
Byetta (exenatide): Exenatide is an injectable medication
Weight loss: Because response to weight loss</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Twice daily
Metabolic Chamber: The subject stays in the small room
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>Mean decrease between pre- and post-randomization in 5 Weeks between the exenatide and placebo groups.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.15"/>
                    <measurement group_id="O2" value="0.27" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Slope</param_type>
            <param_value>-1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.02</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Exenatide</title>
          <description>10 micrograms subcutaneously twice
Byetta (exenatide): Exenatide is an injectable medication
Weight loss: Because response to weight loss</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Twice daily
Metabolic Chamber: The subject stays in the small room
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hunger decrease</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itchiness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jonathan Krakoff</name_or_title>
      <organization>National Institutes of Health</organization>
      <phone>602-200-5217</phone>
      <email>jkrakoff@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

